Search
Cisplatin Treatment Options in Virginia
A collection of 279 research studies where Cisplatin is the interventional treatment. These studies are located in the Virginia, United States. Cisplatin is used for conditions such as Head and Neck Cancer, Lung Cancer and Non-small Cell Lung Cancer.
229 - 240 of 279
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
Completed
This trial is designed to test the efficacy of fluoxetine to improve patient's quality of life during chemotherapy. An innovative application of a selective serotonin reuptake inhibitor may modulate the effects of fatigue, anxiety and depression which worsen quality of life.
Gender:
ALL
Ages:
All
Trial Updated:
07/01/2016
Locations: Martha Jefferson Hospital, Charlottesville, Virginia +2 locations
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
Completed
This study will aims to determine the maximum tolerated dose of CGC-11047 when used in individual combinations with gemcitabine, or docetaxel, or bevacizumab, or erlotinib or cisplatin or 5-flurouracil or sunitinib in one of 7 treatment arms. The dose of CGC-11047 will be escalated until the maximum tolerated dose is established.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2016
Locations: Virginia Oncology Associates, Norfolk, Virginia
Conditions: Cancer
Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether radiation therapy is more effective than combination chemotherapy in treating patients with cancer of the uterus.
PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared to combination chemotherapy in treating patients with cancer of the... Read More
Gender:
FEMALE
Ages:
Between 21 years and 120 years
Trial Updated:
02/10/2016
Locations: Cancer Center at the University of Virginia, Charlottesville, Virginia
Conditions: Sarcoma
Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer
Terminated
This study is being conducted to learn about the safety and risks of using talimogene laherparepvec to treat patients with head and neck cancer and to see if talimogene laherparepvec and chemoradiation together can destroy the tumours versus the use of chemoradiation alone. This study may provide information on the usefulness of talimogene laherparepvec combined with chemoradiation as a future treatment for head and neck cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2016
Locations: VCU Massey Cancer Center, Richmond, Virginia
Conditions: Squamous Cell Carcinoma, Head and Neck Cancer
Calcitriol, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
Terminated
This phase I trial studies the side effects and best dose of calcitriol when given with cisplatin and gemcitabine hydrochloride in treating patients with advanced solid tumors that cannot be removed by surgery. Drugs used in chemotherapy, such as cisplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Calcitriol may stop the growth of tumor cells by blocking blood flow to the tumor. Calcitri... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/11/2016
Locations: Emily Couric Clinical Cancer Center, Charlottesville, Virginia
Conditions: Adult Solid Neoplasm
A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer
Completed
This study is an open-label, dose-escalation study of MM-111 with five different combination treatments with the main goal of determining the safety of MM-111 with each combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/15/2015
Locations: Virginia Oncology Associates, Norfolk, Virginia
Conditions: HER-2 Gene Amplification
S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer
Terminated
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth of esophageal cancer by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and irinotecan, work in different ways to stop the growth of tu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/16/2015
Locations: Danville Regional Medical Center, Danville, Virginia +1 locations
Conditions: Esophageal Cancer
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
Terminated
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving chemotherapy together with radiation therapy is more effective with or without vandetanib in treating patients with head... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2015
Locations: University of Virginia Cancer Center, Charlottesville, Virginia +2 locations
Conditions: Head and Neck Cancer
Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy following surgery may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus radiation therapy in treating patients who have undergone surgery for stage III or stage IV head and neck cancer.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
11/14/2015
Locations: Cancer Center at the University of Virginia, Charlottesville, Virginia +4 locations
Conditions: Head and Neck Cancer
Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Radiation therapy uses high-energy x-rays to damage tumor cells.
PURPOSE: Phase II trial to study the effectiveness of paclitaxel, cisplatin, and filgrastim combined w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2015
Locations: Cancer Center at the University of Virginia, Charlottesville, Virginia +4 locations
Conditions: Head and Neck Cancer
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
Completed
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving chemotherapy together with everolimus before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not ye... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2015
Locations: University of Virginia Health Sciences Center, Charlottesville, Virginia
Conditions: Breast Cancer
S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
Completed
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. It is not yet known whether interferon alfa is more effective with or without combination chemotherapy and interleukin-2 for melanoma.
PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or without... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2015
Locations: Martha Jefferson Hospital Cancer Care Center, Charlottesville, Virginia
Conditions: Melanoma (Skin)
229 - 240 of 279